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Equol has been reported to have greater estrogenic activity and antioxidant capacity than 
its soy isoflavonoid precursor daidzein.  However, only 30 - 50% of humans have 
intestinal microflora capable of converting daidzein to equol.  This suggests that dietary 
supplementation of equol may represent a useful strategy to provide all individuals with 
the health-promoting benefits of this metabolite.  Here we characterized the digestive 
stability and bioaccessibility of equol, as well as its uptake and efflux by differentiated 
Caco-2 cells.  Bovine milk (3.3% fat) supplemented with equol (160 µg) was subjected to 
simulated gastric and small intestinal digestion and the aqueous (bioaccessible) fraction 
was isolated from digesta by centrifugation and filtration (0.2 µm).  Recovery of equol 
following simulated digestion was 106% ± 6%.  Equol efficiently (≥ 93%) partitioned into 
the aqueous fraction of chyme regardless of the amount of bile extract present.  
Monolayers of Caco-2 cells (12 – 15 days post confluent) attached to culture dishes were 
incubated with 2.5 to 20 µM equol to characterize uptake.  After 4 h, cellular content of 
equol was proportional to the medium concentration (r2 = 0.99) and represented 5 to 7% of 
the starting amount of equol.  Intracellular equol was present as the un-conjugated form.  
Maximum accumulation was observed within 1 h of exposure and cellular equol content 
continually declined after 4 h as phase II conjugates of equol were excreted into the 
medium.  In conclusion, equol is stable during simulated digestion, partitions into the 
bioaccessible fraction of chyme, and is rapidly taken up by Caco-2 cells and metabolized 
to phase II conjugates that are excreted.
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• Equol is a microbial metabolite of the isoflavonoid 
daidzein (Figure 1).
• Equol has greater estrogenic activity than daidzein.
• Studies suggest that only 30 - 50% of humans have 
intestinal microflora capable of producing equol.
• Equol supplementation may represent a useful strategy to 
provide all individuals with its proposed health-promoting 
benefits.
1. Characterize the digestive stability and bioaccessibility of 
equol during simulated gastric and small intestinal 
digestion.
2. Characterize equol and daidzein uptake, transport and 
metabolism by differentiated Caco-2 human intestinal 
cells.  
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Add bile extract (0, 1.2, 2.4 or 4.8 mg/mL) 
pancreatin ( 0.4 mg/mL) 
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Equol is stable during simulated digestion and partitions into the aqueous (bioaccessible) 
fraction of digesta.
Uptake of equol and daidzein by Caco-2 cells rapidly reaches its maximum by 1 h.
Equol and daidzein are extensively metabolized to Phase II conjugates that are excreted 
primarily across the apical membrane of small intestinal mucosa epithelial cells.  This suggests 
that the bioavailability of equol is limited and may contribute to classification of
≤ 50% of individuals as “non-producers.”
Despite limited bioavailability of equol, supplementation may provide individuals with its 
health-promoting benefits.
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Uptake Experiments
Dose: 2.5 to 20 µmol/L for 4h
Time: 0.5 to 8 h (10 µmol/L)
Transepithelial Transport Experiments
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Culture of Caco-2 Cells
Figure 1.  Metabolism of Daidzin to Equol
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Figure 2
Equol is stable during simulated gastric and small intestinal digestion.  Partitioning of 
equol into the aqueous (bioaccessible) fraction of the digesta was > 90% regardless of the 
bile salt concentration.
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Figure 3
Uptake of equol (Panel A) and daidzein (Panel B) by Caco-2 cells cultured on plastic is directly proportional (r2 ≥ 0.99) to the medium 
concentration.  Uptake of equol is approximately 10-fold greater than that of daidzein for each treatment concentration.
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Figure 4
Uptake of equol (Panel A) and daidzein (Panel B) by Caco-2 cells cultured on plastic is rapid with maximum intracellular levels attained 
within 1 h of incubation.  Intracellular equol begins to decline by 2 h suggesting efflux is occurring.  Intracellular levels of daidzein remained 
consistent for each incubation period.  
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Figure 5
Uptake of equol (Panel A) by Caco-2 cells 
cultured on transwell inserts reaches a 
maximum within 1 h.  The amount of 
intracellular equol declines rapidly as Phase II 
conjugates are excreted across the apical 
(Panel B) and basolateral (Panel C) membranes.  
By 8h, nearly all of the equol added at 0 h has 
been metabolized to Phase II conjugates.  
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Figure 6
Daidzein in the apical and 
basolateral compartments is 
predominantly free at 2 h (Panel A).    
Phase II metabolites are the primary 
species in the apical compartment 
by 8 h (Panel B), whereas similar 
amounts of free and conjugated 
daidzein are present in the 
basolateral compartment.  Neither 
free nor conjugated daidzein was 
detected in cells grown on inserts. 
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SPECIFIC AIMS
SUMMARY & CONCLUSIONS
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Figure 7
Schematic representation of transepithelial transport and metabolism of equol.  The participation 
of multidrug resistance proteins in efflux of phase II metabolites of equol is currently being 
investigated.  (ABCB1 = PgP, MDR1; ABCC1 = MRP1; ABCC2 = MRP2; ABCC3 = MRP3)
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